Gelesis Revenue and Competitors

Boston, MA USA

Location

$312.8M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Gelesis's estimated annual revenue is currently $11.9M per year.(i)
  • Gelesis's estimated revenue per employee is $155,000
  • Gelesis's total funding is $312.8M.

Employee Data

  • Gelesis has 77 Employees.(i)
  • Gelesis grew their employee count by -37% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Gelesis is a registrational-stage biotechnology company developing a novel category of first-in-class therapies for weight loss and GI-related diseases. Our platform uses a clinically validated hydrogel technology composed of naturally derived building blocks. The Gelesis portfolio includes a product for obesity and overweight and a pipeline with potential therapies for Non-alcoholic Fatty Liver Disease (NAFLD)/ Non-alcoholic Steatohepatitis (NASH), Type 2 diabetes and Chronic Idiopathic Constipation (CIC). Gelesis is headquartered in Boston, Mass. and was founded by PureTech Health and a group of leading obesity researchers. Gelesis is led by a strong management team, with expertise in medicine, materials science, manufacturing and commercialization. Our scientific advisory board and clinical advisors are leading experts in obesity and chronic disease. Community guidelines: http://bit.ly/2Q8VfUG

keywords:Biotechnology

$312.8M

Total Funding

77

Number of Employees

$11.9M

Revenue (est)

-37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Gelesis News

2022-04-20 - Gelesis' Proprietary Superabsorbent Hydrogel Induced ...

Gelesis' Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species...

2022-04-19 - Where Will Gelesis Holdings Inc (GLS) Stock Go Next After It Has Risen 9.73% in a Week?

Gelesis Holdings Inc (GLS) stock has risen 9.73% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

2022-04-13 - Gelesis Holdings: Advancing Biomimetic Superabsorbent Hydrogels For GI-Related Diseases

The Company is evaluating and investigating its technology in GI-related diseases. Gelesis consummated a business combination with an SPAC in...

2021-11-18 - Gelesis Receives $30 Million Plenity Order from Ro

Gelesis announced today that leading U.S. direct-to-patient healthcare company Ro has placed a $30 million fully paid pre-order for the company’s first commercial product for weight management, Plenity®. Plenity was initially made available through a beta launch in 2020, and demand quickly outpa ...

2021-11-18 - PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, announced today that its Founded Entity, Gelesis, Inc. (“Gelesis”) received a $30 million fully paid pre-order for the company’s first commercial product for weight management, ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M77-6%N/A
#2
$18.9M77-31%N/A
#3
$7.5M77-1%N/A
#4
$11.9M77N/AN/A
#5
$19.4M773%N/A